• The Journal of Internal Korean Medicine
• /
• v.38 no.5
• /
• pp.564-575
• /
• 2017

Objectives: This clinical report describes one patient with the clinical characteristics of burning mouth syndrome accompanied by oro-facial dyskinesia. Methods: The patient with burning mouth syndrome and jaw tremor was treated using the following Korean medicine treatments: the herbal medicines Yukgunja-tang-gami (六君子湯加味) and Sibak-tang-gami (柴朴湯加味) and acupuncture for 16 days, together with 10 Se-sim (Uncaria Ramulus et Uncus) pharmacopuncture procedures. Patient symptoms were evaluated daily using a Visual Analog Scale questionnaire and twice using the STAI (State-Trait Anxiety Inventory) questionnaire. Results: After the treatments, the oro-facial dyskinesia and burning sensation on the tongue were improved by 62.5%. The mental state of anxiety, regarded as the reason for these complaints, was also improved, based on the State-Trait Anxiety Inventory results (67/61 versus 57/52). We found that the improvement was better when combining Se-sim (Uncaria Ramulus et Uncus) pharmacopuncture with the conventional herbal medicine and acupuncture used in Korean medicine. Conclusion: Korean medicine treatments may be valuable for patients with burning mouth syndrome and oro-facial dyskinesia.

• Journal of Oral Medicine and Pain
• /
• v.48 no.4
• /
• pp.131-136
• /
• 2023

Burning mouth syndrome (BMS), a chronic pain disorder with an unclear etiology, is characterized by a burning sensation in the oral cavity. The absence of objective diagnostic methods for this condition complicates its diagnosis and treatment. Recently, efforts have been ongoing to find biomarkers for the diagnosis and evaluation of patients with BMS. Several studies have reported hematological changes, differences in salivary protein composition, and peripheral neuropathy in the affected oral tissues. This review summarizes the research regarding the objective changes observed in patients with BMS to identify potential diagnostic approaches.

• Journal of the Korean Association of Oral and Maxillofacial Surgeons
• /
• v.50 no.2
• /
• pp.63-69
• /
• 2024

This current systematic review aimed to evaluate the current evidence on the effect of topical capsaicin application to alleviate symptoms related to burning mouth syndrome (BMS). PubMed, Ovid SP, and Cochrane were searched from 1980 to 2022 to identify relevant literature. A total of 942 titles (PubMed, 84; Ovid SP, 839; Cochrane, 19) was retrieved, of which 936 were excluded based on the title and abstract. A total of 11 studies were further evaluated for full text analysis, of which 7 were excluded. As a result, 4 articles were included for qualitative synthesis of data. Capsaicin as a mouthwash can have potential application in the treatment of symptoms related to burning mouth. The quality of available studies is moderate to low, and a well-designed randomized multicentric study comparing capsaicin with other active agents is planned to obtain more definitive conclusions.

• Journal of Oral Medicine and Pain
• /
• v.21 no.1
• /
• pp.133-140
• /
• 1996

Saliva have many important functions in the maintenance of oral health. Saliva contains protective components, antibacterial enzymes, and other rubricating glycoprotein elements. When the salivary flow decreases of the salivary composition changes, a normally healthy mouth can become susceptible to caries, periodontal disease, and mucositis, and other diseases. Salivary peroxidase system acts as an antimicrobial factor in the oral cavity, having a role in the prevention of dental plaque accumulation, dental caries and gingivitis. Recently, this enzyme system has been introduced by many researchers in the form of toothpaste, mouthwash or moisturizing gel for use in patients with various disease states . The author prescribed the peroxidase system containing gel (Oralbalance) to the 18 Burning Mouth Syndrome (BMS) patients for 1 week and investigated the changes of the subjective symptoms, $HOSCN/OSCN^-$ levels of unstimulated whole saliva, and the salivary flow rates. The obtained results were as follows : 1. The patients reported decrease in all symptoms of BMS after the use of peroxidase system containing gel, particulary, a significantly higher decreases of dry mouth and burning symptoms. 2. Decreased $HOSCN/OSCN^-$ levels of unstimulated whole saliva were detected in the patients with BMS after the use of perosidase system containing gel for 1 week. 3. There was no difference between the flow rates of unstimulated whole saliva before and after uses of peroxidase system containing gel for 1 week.

• Journal of Oral Medicine and Pain
• /
• v.36 no.2
• /
• pp.91-97
• /
• 2011

Helicobacter pylori (H. pylori) is bacterial infection, with more than half of the world population infected and relates to many oral disease such oral lichen planus, recurrent aphthous ulceration, periodontal disease and halitosis and so on. Burning mouth syndrome(BMS) is defined as a burning sensation of the oral mucosa, lips, and/or tongue, in the absence of specific oral lesions. The etiology of BMS is suggested local, systemic and psychological factors and researchs related BMS and to infection of H. pyloir in the oral cavity are few. The purpose of this study was to evaluate relationship between burning mouth syndrome and H. pylori in the oral cavity. We recruited 21 subjects with burning mouth syndrome and 21 subjects as control group. Samples in the oral cavity were taken area of buccal mucosa, dorsum of the tongue and saliva. We analysed samples by nested polymerase chain reaction(PCR). The results were as follows: 1. Among 21 patients with burning mouth sydrome and 21 subjects of control group, 6(29%) and 3(14%) were positive respectively(P>0.05). 2. In detection rate of H. pylori in area taken sample, 3(14%), 2(10%) and 4(19%) were positive in buccal mucosa, dorsum of the tongue and saliva of patient and 2(10%) and 1(5%) were positive in dorsum of the tongue and saliva of control group(P>0.05). Conclusively, we can guess that H. pylori in the oral cavity is not related with burning mouth syndrome.

• Journal of Oral Medicine and Pain
• /
• v.48 no.1
• /
• pp.11-15
• /
• 2023

Burning mouth syndrome (BMS) is a chronic idiopathic orofacial pain. BMS is currently classified as a neuropathic pain condition, but it is difficult to pinpoint the precise neuropathic mechanisms involved in each patient. It is challenging to complete the cure for BMS. Clinicians should treat BMS patients based on evidence. There is pharmacological and non-pharmacological therapy in the treatment modalities of BMS. The provision of objective information and reassurance as part of cognitive behavioral therapy is critical in the treatment of BMS. This paper will review the evidence-based treatment of BMS and discuss what we need to do.

• Journal of Oral Medicine and Pain
• /
• v.44 no.3
• /
• pp.83-91
• /
• 2019

Purpose: Venlafaxine and duloxetine have been shown to be effective in the treatment of neuropathic pain disorders. However, knowledge about the efficacy of venlafaxine and duloxetine on burning mouth syndrome (BMS) is still insufficient. The purpose of this study was to investigate the efficacy of venlafaxine and duloxetine on refractory BMS patients. Methods: Twelve refractory BMS patients who were prescribed venlafaxine or duloxetine were included in this study. These patients did not respond to previous administration of clonazepam, alpha-lipoic acid, gabapentin, and nortriptyline. All participants were the primary type of BMS patients who had no local and systemic factors related to the oral burning sensation. The intensities of oral symptoms following venlafaxine or duloxetine administration were compared with those before administration and at baseline. Results: Venlafaxine and duloxetine were prescribed to four and nine patients, respectively. One patient was prescribed both medications in turn. Among them, only two patients showed improvement of oral symptoms without side effects. In the other ten patients, symptoms failed to improve. Six of them reported that the drug was ineffective, and four of them stopped taking the medications on their own due to intolerable side effects, such as insomnia, constipation, drowsiness, dizziness, and xerostomia. Conclusions: Venlafaxine and duloxetine may only relieve oral symptoms in a minority of refractory BMS patients. Further large-scale studies are needed to determine the potential clinical factors that could predict the efficacy of venlafaxine and duloxetine.

• Journal of Oral Medicine and Pain
• /
• v.37 no.1
• /
• pp.1-7
• /
• 2012

Burning mouth syndrome(BMS) refers to a chronic orofacial pain disorder usually unaccompanied by mucosal lesions or other clinical signs. Tongue(anterior and lateral border) is found to be the most common site for the burning sensations in the oral cavity, and various oral sites may be affected including hard palate and lips. The etiology of this disorder remains poorly understood, but the various factors might be related with the pathogenesis of the BMS. These factors have been devided into local, systemic and psychological. Recently, there have been increasing reports that the pain of BMS may be neuropathic in origin. The complex and multifactorial etiology of BMS necessitates multidisciplinary approach for the management of these patients. Recently, several studies have reported that oral parafunctional habits could be related the pathogenesis of BMS, and tried to control the symptom of BMS with various methods. We reported the cases who had the symptom of burning mouth syndrome with removable anti-nociceptive appliance in the lower dentition.

• Journal of Oral Medicine and Pain
• /
• v.41 no.4
• /
• pp.188-194
• /
• 2016

Purpose: Burning mouth syndrome (BMS) is ambiguous and enigmatic oral condition. Sleep disturbance is one of the most prevalent complaints of patients with chronic pain. The aim of this study was to estimate general sleep characteristics and propensity in patients with BMS. Methods: A total of thirty BMS patients and thirty healthy control subjects were investigated. Self-reported measures of sleep quality were conducted using two widely used methods; the Pittsburgh Sleep Quality Index (PSQI) and Epworth Sleepiness Scale (ESS). Data were analyzed with one-way ANOVA, chi-square, Fisher's exact test, Kruskal-Wallis test, Holm method with 95% confidence interval and p<0.05 significant level. Results: BMS patients showed more poor sleepers than those in control subjects in both ESS and PSQI test. BMS patients also showed statistically significant poorer sleep quality compared with control subjects in both test. When BMS group were divided into three groups on the basis of numeric rating scale, the higher score subjects had, the more mean rank they had in the PSQI. Conclusions: BMS patients showed up poor sleep characteristics and propensity than control group, and they also showed the more severe the pain was, the worse the sleep quality was.

• The Journal of Internal Korean Medicine
• /
• v.38 no.4
• /
• pp.455-467
• /
• 2017

Objectives: This study evaluated the correlation between taste function and spleen qi deficiency in patients with burning mouth syndrome (BMS) and compared subgroups of BMS (i.e., dysgeusia and non-dysgeusia subgroups). Methods: This study included 60 participants categorized into two groups: a BMS group and healthy control (HC) group. Taste threshold was measured within six levels using solutions of four basic taste qualities. Subjects' Oral Health Impact Profiles (OHIPs-14) and Spleen qi Deficiency Questionnaire (SQDQ) scores were analyzed. Results: Taste thresholds for sweet (sucrose) and salty (NaCl) tastes were significantly lower in the BMS group than in the HC group, but sour (citric acid) and bitter (quinine HCl) tastes showed no significant differences between groups. In the dysgeusia and non-dysgeusia subgroups, no significant differences in the four basic taste thresholds were found. SQDQ scores were significantly higher in the BMS group compared to the HC and in the dysgeusia group compared to the non-dysgeusia group. OHIPs-14 and SQDQ scores for the BMS group were significantly and positively correlated. Conclusions: Spleen qi deficiency is related to taste function and can be used to treat BMS patients with taste dysfunction.